143B
|
IC50 |
12.25 μM
Compound: AZT, Zidovudine
|
Cytotoxicity against human 143B cells after 72 hrs by MTT assay
Cytotoxicity against human 143B cells after 72 hrs by MTT assay
|
[PMID: 25440502]
|
143B
|
IC50 |
148.42 μM
Compound: AZT, Zidovudine
|
Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay
Cytotoxicity against human thymidine kinase-deficient 143B cells after 72 hrs by MTT assay
|
[PMID: 25440502]
|
5637
|
IC50 |
|
Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity in human 5637 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 30108758]
|
5637
|
IC50 |
|
Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human 5637 cells assessed as growth inhibition after 48 hrs by MTT assay
|
[PMID: 25811955]
|
A549
|
IC50 |
|
Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
Inhibition of Influenza A virus (A/Viet Nam/1203/2004(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
|
[PMID: 19537689]
|
A549
|
IC50 |
|
Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
Inhibition of Influenza A virus (A/Bar-headed Goose/Qinghai/59/05(H5N1)) hemagglutininin-mediated viral entry into human A549 cells assessed as luciferase activity after 48 hrs postinfection by luminometry
|
[PMID: 19537689]
|
A549
|
IC50 |
11.86 μM
Compound: 3; AZT
|
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
A549
|
IC50 |
16.19 μM
Compound: 13, AZT
|
Cytotoxicity against human A549 cells after 48 hrs by SRB method
Cytotoxicity against human A549 cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
AA5
|
IC50 |
< 0.0003 μM
Compound: AZT
|
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
AA5
|
IC50 |
|
Cytotoxicity against human AA5 cells by MTS assay
Cytotoxicity against human AA5 cells by MTS assay
|
[PMID: 20086149]
|
AA5
|
IC50 |
|
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
AA5
|
IC50 |
|
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
AA5
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
AA5
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
AA5
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
B(EBV+)
|
EC50 |
|
Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay
Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay
|
[PMID: 7932526]
|
Bel-7402
|
EC50 |
4.62 μM
Compound: Zidovudine
|
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
|
[PMID: 18313175]
|
Bone marrow cell
|
CC50 |
0.5 μM
Compound: ZDV, AZT
|
Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay
Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay
|
[PMID: 20439609]
|
Bone marrow cell
|
CC50 |
0.89 μM
Compound: ZDV, AZT
|
Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay
Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay
|
[PMID: 20439609]
|
BxT
|
EC50 |
|
Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay
Effective concentration required for antiviral activity against BxT cell line of 174xCEM cells of Human by XTT assay
|
[PMID: 7932526]
|
C3H/3T3
|
EC50 |
|
Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.
Concentration of compound required to inhibit HIV-1 induced cytopathogenicity of MSV-induced transformation of C3H/3T3 cells by 50%.
|
[PMID: 2016718]
|
C8166
|
CC50 |
|
Cytotoxicity against C8166 cells by MTT assay
Cytotoxicity against C8166 cells by MTT assay
|
[PMID: 16279773]
|
C8166
|
CC50 |
> 100 μg/mL
Compound: AZT
|
Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay
Cytotoxicity against HIV1 infected human C8166-CCR5 cells assessed as decrease in cell viability by cell associated dehydrogenase activity assay
|
[PMID: 19515569]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 19413342]
|
C8166
|
CC50 |
|
Concentration which reduces the viability of uninfected C8166 cells by 50%
Concentration which reduces the viability of uninfected C8166 cells by 50%
|
10.1016/0960-894X(96)00446-5
|
C8166
|
CC50 |
|
Concentration of compound required to reduce viability of C8166 cells by 50%.
Concentration of compound required to reduce viability of C8166 cells by 50%.
|
10.1016/0960-894X(96)00444-1
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
Cytotoxicity against human C8166 cells assessed as inhibition of cell viability after 3 days by MTT assay
|
[PMID: 23368966]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against C8166 cells after 72 hrs by MTT method
Cytotoxicity against C8166 cells after 72 hrs by MTT method
|
[PMID: 17489633]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 23327759]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 23078294]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 20146529]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells by MTT method
Cytotoxicity against human C8166 cells by MTT method
|
[PMID: 18088099]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells by MTT method
Cytotoxicity against human C8166 cells by MTT method
|
[PMID: 16643044]
|
C8166
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 16499331]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
|
[PMID: 23738539]
|
C8166
|
CC50 |
> 749 μM
Compound: AZT, zidovudine
|
Cytotoxicity against human C8166 cells after 72 hrs by MTT method
Cytotoxicity against human C8166 cells after 72 hrs by MTT method
|
[PMID: 18316190]
|
C8166
|
EC50 |
0.00152 μM
Compound: AZT; zidovudine
|
Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
Antiviral activity against HIV1 74V infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 4 hrs followed by cell plating for 72 hrs by ELISA method
|
[PMID: 27039251]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
Antiviral activity against HIV1 3B infected human C8166 cells assessed as inhibition of syncytia formation by p24 antigen based assay
|
[PMID: 19170521]
|
C8166
|
EC50 |
0.0034 μg/mL
Compound: AZT
|
Antiviral activity against HIV1 in C8166 cells after 72 hrs
Antiviral activity against HIV1 in C8166 cells after 72 hrs
|
[PMID: 18088099]
|
C8166
|
IC50 |
|
Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain
|
10.1016/0960-894X(95)00257-T
|
C8166
|
EC50 |
0.00436 μM
Compound: AZT; zidovudine
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as reduction in p24 antigen level incubated for 2 hrs followed by cell plating for 72 hrs by ELISA method
|
[PMID: 27039251]
|
C8166
|
EC50 |
0.00794 μM
Compound: AZT; zidovudine
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as cytopathic effect by counting the number of syncytia by microscopy
|
[PMID: 27039251]
|
C8166
|
EC50 |
|
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB A17 harboring reverse transcriptase K103N and Y181C double mutant infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction
|
[PMID: 21689939]
|
C8166
|
EC50 |
|
Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy
Antiviral activity against HIV-1 3B infected in C8166 cells assessed as virus-induced cytopathic effect measuring scintia formation after 3 days by microscopy
|
[PMID: 23046280]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay
Antiviral activity against HIV1 in human C8166 cells assessed as protection against viral-induced cytopathic effect by syncytium reduction assay
|
[PMID: 18396905]
|
C8166
|
EC50 |
0.011 μM
Compound: AZT, zidovudine
|
Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay
Antiviral activity against HIV1 3B in C8166 cells by syncytium reduction assay
|
[PMID: 18316190]
|
C8166
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
|
[PMID: 21788138]
|
C8166
|
EC50 |
0.013 μM
Compound: Zidovudine
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathic effect by measuring syncytia formation after 72 hrs by inverted microscopic method
|
[PMID: 27894873]
|
C8166
|
EC50 |
0.016 μg/mL
Compound: AZT
|
Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA
Antiviral activity against HIV1 MN infected in human C8166 cells assessed as reduction in antigen gp120 production by ELISA
|
[PMID: 11374977]
|
C8166
|
EC50 |
|
Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
Tested against HIV-1 111B for Inhibition of viral replication by determining reduction of syncytia formation and antigen gp120 in C8166 cells, estimated by ELISA
|
10.1016/S0960-894X(97)00022-X
|
C8166
|
EC50 |
|
Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days
Antiviral activity against on HIV1 3b infected C8166 cells assessed as syncytial cell formation after 3 days
|
[PMID: 17291043]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of syncytia after 3 days
|
[PMID: 23099098]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity by syncytium formation assay
|
[PMID: 24299567]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against HIV1 A17 harbouring RT K103N/Y181C mutant infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
|
[PMID: 23164656]
|
C8166
|
EC50 |
|
Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
Antiviral activity against wild type HIV1 A17 harboring reverse transcriptase K103N and Y181C mutant infected in human C8166 cells assessed as inhibition of viral-induced cytopathogenicity after 3 days by syncytium formation assay
|
[PMID: 21788138]
|
C8166
|
EC50 |
|
Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
Antiviral activity against HIV1 A17 expressing reverse transcriptase K103N/Y181C double mutant infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
|
[PMID: 21719299]
|
C8166
|
EC50 |
|
Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells
Concentration required to inhibit p24 viral antigen production by 50% in C-8166 cells
|
10.1016/0960-894X(95)00208-B
|
C8166
|
EC50 |
0.034 μg/mL
Compound: AZT
|
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of syncytia formation after 3 days
|
[PMID: 23368966]
|
C8166
|
EC50 |
|
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay
|
[PMID: 23738539]
|
C8166
|
EC50 |
|
Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against Human immunodeficiency virus 2 ROD infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
|
[PMID: 21689939]
|
C8166
|
EC50 |
|
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against 0.06 MOI Human immunodeficiency virus 1 IIIB infected in C8166 cells assessed as reduction in virus-induced cytopathic effect after 3 days by syncytium reduction assay
|
[PMID: 21689939]
|
C8166
|
CC50 |
1139.47 μg/mL
Compound: AZT
|
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
|
[PMID: 20488700]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
|
[PMID: 20598530]
|
C8166
|
EC50 |
|
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against wild type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
|
[PMID: 23164656]
|
C8166
|
EC50 |
|
Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
Antiviral activity against wild-type HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days by measuring syncytia under inverted microscope
|
[PMID: 21719299]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 19685905]
|
C8166
|
EC50 |
|
Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
Antiviral activity against HIV2 ROD infected in human C8166 cells assessed as protection against virus-induced cytopathic effect after 3 days by syncytium reduction assay
|
[PMID: 23164656]
|
C8166
|
EC50 |
|
Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope
Antiviral activity against HIV-2 ROD infected in human C8166 cells assessed as protection against viral cytopathogenicity after 3 days by measuring syncytia under inverted microscope
|
[PMID: 21719299]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
Cytotoxicity against human C8166 cells assessed as reduction in cell viability incubated for 3 days by MTT assay
|
[PMID: 34812640]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 21650224]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 21534540]
|
C8166
|
EC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human C8166 cells assessed as numbers of syncytia after 3 days by MTT assay
|
[PMID: 21561060]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
|
[PMID: 21561060]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
|
[PMID: 23046280]
|
C8166
|
CC50 |
|
Cytotoxicity against C8166 cells by MTT method
Cytotoxicity against C8166 cells by MTT method
|
[PMID: 17291043]
|
C8166
|
CC50 |
4676.07 μM
Compound: AZT; zidovudine
|
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
|
[PMID: 27039251]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 26214125]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay
Cytotoxicity against human C8166 cells assessed as decrease in cell viability by MTT assay
|
[PMID: 23164656]
|
C8166
|
CC50 |
|
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days
Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days
|
[PMID: 21194939]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
|
[PMID: 18396905]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 3 days by MTT assay
Cytotoxicity against human C8166 cells after 3 days by MTT assay
|
[PMID: 23099098]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells after 72 hrs by MTT assay
|
[PMID: 30596489]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 21788138]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT colorimetric assay
Cytotoxicity against human C8166 cells by MTT colorimetric assay
|
[PMID: 21719299]
|
C8166
|
CC50 |
|
Cytotoxicity against human C8166 cells by MTT assay
Cytotoxicity against human C8166 cells by MTT assay
|
[PMID: 21689939]
|
C8166
|
CC50 |
|
Cytotoxicity against C8166 cells by MTT assay
Cytotoxicity against C8166 cells by MTT assay
|
[PMID: 17315963]
|
C8166
|
CC50 |
5858.85 μM
Compound: Zidovudine
|
Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay
Cytotoxicity against human C8166 cells measured after 72 hrs by MTT assay
|
[PMID: 27894873]
|
Caco-2
|
IC50 |
0.006 mg/mL
Compound: AZT
|
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
|
[PMID: 17337193]
|
Caco-2
|
IC50 |
0.015 mg/mL
Compound: AZT
|
Growth inhibition of human Caco-2 cells after 72 hrs
Growth inhibition of human Caco-2 cells after 72 hrs
|
[PMID: 17079149]
|
Caco-2
|
IC50 |
0.015 mg/mL
Compound: AZT
|
Cytotoxicity against human Caco-2 cells after 72 hrs
Cytotoxicity against human Caco-2 cells after 72 hrs
|
[PMID: 17079149]
|
Caco-2
|
IC50 |
|
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
|
[PMID: 17555969]
|
Caco-2
|
IC50 |
|
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as inhibition of infectivity following virus attachment after 72 hrs
|
[PMID: 18037195]
|
Caco-2
|
IC50 |
|
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
Antiviral activity against rotavirus RF infected human Caco-2 cells following viral attachment after 72 hrs
|
[PMID: 17337193]
|
Caco-2
|
CC50 |
|
Cytotoxicity against human Caco-2 cells after 72 hrs
Cytotoxicity against human Caco-2 cells after 72 hrs
|
[PMID: 18037195]
|
Caco-2
|
CC50 |
|
Cytotoxicity against human Caco-2 cells after 72 hrs
Cytotoxicity against human Caco-2 cells after 72 hrs
|
[PMID: 17548129]
|
Caco-2
|
IC50 |
|
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs
Antiviral activity against Rotavirus RF in human Caco-2 cells assessed as neutralization of virus in solution before its attachment after 72 hrs
|
[PMID: 17555969]
|
Caco-2
|
IC50 |
|
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs
Antiviral activity against rotavirus RF in human Caco-2 cells assessed as neutralization of virus before its attachment after 72 hrs
|
[PMID: 18037195]
|
CCRF-CEM
|
EC50 |
|
Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells
Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells
|
[PMID: 11170632]
|
CCRF-CEM
|
CC50 |
> 100 μg/mL
Compound: AZT
|
Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.
Cytotoxic concentration which is required to reduce human CEM cell viability by 50%.
|
[PMID: 9046339]
|
CCRF-CEM
|
IC50 |
> 100 μM
Compound: 27, L-AZT
|
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
|
[PMID: 21700368]
|
CCRF-CEM
|
CC50 |
> 100 μM
Compound: 1b; AZT
|
Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
Cytotoxicity in human CEM/0 cells assessed as reduction in cell viability incubated for 4 to 5 days
|
[PMID: 32515595]
|
CCRF-CEM
|
EC50 |
> 100 μM
Compound: 3 (AZT)
|
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM-TK- cells.
|
10.1016/0960-894X(96)00195-3
|
CCRF-CEM
|
CC50 |
|
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM/TK cells
|
[PMID: 12593658]
|
CCRF-CEM
|
EC50 |
|
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM/TK cells
|
[PMID: 12593658]
|
CCRF-CEM
|
CC50 |
> 125 μg/mL
Compound: zidovudine
|
Cytotoxic concentration required to reduce CEM cell viability by 50%
Cytotoxic concentration required to reduce CEM cell viability by 50%
|
[PMID: 8709116]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days
Cytotoxicity against human CEM/0 cells assessed as reduction in cell proliferation incubated for 4 to 5 days
|
[PMID: 26125628]
|
CCRF-CEM
|
CC50 |
|
Concentration of compound required to reduce viability of CEM/0 cells by 50%.
Concentration of compound required to reduce viability of CEM/0 cells by 50%.
|
10.1016/0960-894X(96)00444-1
|
CCRF-CEM
|
CC50 |
|
Concentration required to reduce cell viability of CEM/0 cells by 50%
Concentration required to reduce cell viability of CEM/0 cells by 50%
|
10.1016/0960-894X(96)00443-X
|
CCRF-CEM
|
CC50 |
|
Concentration required to reduce CEM/0 cell viability by 50%
Concentration required to reduce CEM/0 cell viability by 50%
|
[PMID: 11356105]
|
CCRF-CEM
|
IC50 |
0.003 μg/mL
Compound: AZT
|
compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells
compound tested for inhibitory activity by plaque reduction assay against HIV-1 in CEM cells
|
[PMID: 9548818]
|
CCRF-CEM
|
EC50 |
|
Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells
Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells
|
[PMID: 11714616]
|
CCRF-CEM
|
EC50 |
|
Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells
Effective concentration required to inhibit HIV-2 induced cytopathicity by 50% in CEM cells
|
[PMID: 11714616]
|
CCRF-CEM
|
EC50 |
0.005 μM
Compound: 3 (AZT)
|
Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
Compound was evaluated for the inhibition of HIV replication using HIV-1 infected CEM cells.
|
10.1016/0960-894X(96)00195-3
|
CCRF-CEM
|
EC50 |
|
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-2 by 50%.
|
[PMID: 11356105]
|
CCRF-CEM
|
EC50 |
|
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.
Concentration required to protect CEM/0 cells against the cytopathicity of HIV-1 by 50%.
|
[PMID: 11356105]
|
CCRF-CEM
|
EC50 |
0.008 μM
Compound: 3 (AZT)
|
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
Compound was evaluated for the inhibition of HIV replication using HIV-2 infected CEM cells.
|
10.1016/0960-894X(96)00195-3
|
CCRF-CEM
|
EC50 |
0.012 μM
Compound: 4, AZT
|
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV1 3B infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
EC50 |
0.067 μM
Compound: 4, AZT
|
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
Antiviral activity against HIV2 ROD infected in human CEM cells assessed as virus-induced giant cell formation after 4 days by microscopic analysis
|
[PMID: 24177359]
|
CCRF-CEM
|
ED50 |
|
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 11.
|
[PMID: 1712047]
|
CCRF-CEM
|
ED50 |
|
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 7.
|
[PMID: 1712047]
|
CCRF-CEM
|
ED50 |
|
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 19.
|
[PMID: 1712047]
|
CCRF-CEM
|
ED50 |
|
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.
Concentration that reduced by 50% the HIV induced CPE (cytopathic effect) on day 22.
|
[PMID: 1712047]
|
CCRF-CEM
|
EC50 |
|
Cytotoxicity against african human CEM cells after 6 days by XTT assay
Cytotoxicity against african human CEM cells after 6 days by XTT assay
|
[PMID: 20691339]
|
CCRF-CEM
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA
Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected human CEM cells expressing GFP measured up to 8 days postinfection by p24 antigen capture ELISA
|
[PMID: 20350812]
|
CCRF-CEM
|
EC50 |
|
Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA
Antiviral activity against 0.05 MOI Human immunodeficiency virus 1 NL4.3 infected in human CEM cells expressing green fluorescent protein assessed as p24 antigen production measured 7 days post infection by ELISA
|
[PMID: 21295891]
|
CCRF-CEM
|
IC50 |
|
Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry
Antiviral activity against HIV1 NL4-3 infected in GFP expressing human CEM cells assessed as inhibition of viral infection measured after 9 days postinfection by microfluorometry
|
[PMID: 20137956]
|
CCRF-CEM
|
EC50 |
|
Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA
Antiviral activity against HIV1 NL4.3 infected in human CEM-GFP T cells assessed as inhibition of p24 antigen production after 7 days by ELISA
|
[PMID: 21227704]
|
CCRF-CEM
|
IC50 |
|
Compound was evaluated for its toxicity by Calorimetric assay in CEM
Compound was evaluated for its toxicity by Calorimetric assay in CEM
|
[PMID: 9357530]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 3 days by MTT assay
Cytotoxicity against human CEM cells after 3 days by MTT assay
|
[PMID: 19153047]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion assay
|
[PMID: 21700368]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
Cytotoxicity against human CEM cells assessed as reduction in cell viability after 5 days by Cell Titer 96 Aqueous One Solution cell proliferation assay
|
[PMID: 25701249]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 5 days
Cytotoxicity against human CEM cells after 5 days
|
[PMID: 19948402]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
Cytotoxicity against human CEM cells after 6 days by trypan blue exclusion method
|
[PMID: 22014549]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 6 days
Cytotoxicity against human CEM cells after 6 days
|
[PMID: 17158051]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay
Cytotoxicity against Homo sapiens (human) CEM cells after 5 days celltiter 96 aqueous assay
|
10.1007/s00044-011-9912-x
|
CCRF-CEM
|
IC50 |
|
Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration
Ability to reduce viable cell number on HIV-1-infected CEM cells in mice after intraperitoneal administration
|
[PMID: 8627600]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay
Cytotoxicity against human CEM cells expressing green fluorescent protein by MTT assay
|
[PMID: 20598537]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay
Cytotoxicity against human CEM cells expressing GFP after 48 to 72 hrs by MTT assay
|
[PMID: 20350812]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay
Cytotoxicity against human CEM cells expressing green fluorescent protein after 48 hrs by MTT assay
|
[PMID: 21295891]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay
Cytotoxicity against GFP expressing human CEM cells after 48 to 72 hrs by MTT assay
|
[PMID: 20137956]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay
Cytotoxicity against human CEM-GFP cells after 48 hrs by MTT assay
|
[PMID: 21227704]
|
CCRF-CEM
|
CC50 |
|
compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells
compound tested for anti-HIV-1 activity by plaque reduction assay against HIV-1 in CEM cells
|
[PMID: 9548818]
|
CCRF-CEM
|
IC50 |
|
Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay
Antiviral activity against HIV1 infected in human CEM cells assessed as protection against virus-induced cytopathic effect after 6 days by XTT assay
|
[PMID: 20691339]
|
CCRF-CEM
|
IC50 |
|
Cytotoxicity against human CEM cells after 5 days by trypan blue assay
Cytotoxicity against human CEM cells after 5 days by trypan blue assay
|
[PMID: 21371895]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
Cytotoxicity against human CEM cells assessed as reduction in cell growth incubated for 5 days by CellTiter 96 AQueous One Solution cell proliferation assay
|
[PMID: 26451771]
|
CCRF-CEM
|
CC50 |
|
Concentration required to reduce the viability of mock-infected CEM cells by 50%
Concentration required to reduce the viability of mock-infected CEM cells by 50%
|
[PMID: 11714616]
|
CCRF-CEM
|
IC50 |
|
Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay
Antiviral activity against HIV1 infected in CEM cells after 72 hrs by GFP reporter gene assay
|
[PMID: 22549138]
|
CCRF-CEM
|
CC50 |
|
Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay
Cytotoxicity against human CEM cells after 2 to 4 days by MTT assay
|
[PMID: 19596885]
|
CEM-c113
|
CC50 |
|
Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells
Concentration required to reduce by 50% the viability of noninfected treated CEM-CL13 cells
|
[PMID: 9154976]
|
CEM-c113
|
EC50 |
|
Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.
Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by MTT assay.
|
[PMID: 8385224]
|
CEM-SS
|
IC50 |
|
Cytotoxicity against human CEM-SS cells by MTS assay
Cytotoxicity against human CEM-SS cells by MTS assay
|
[PMID: 20086149]
|
CEM-SS
|
CC50 |
> 1 μM
Compound: AZT, 3'-azidothymidine
|
Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay
Cytotoxicity against human CEM-SS cells assessed as cell viability after 6 days by MTS assay
|
[PMID: 24102161]
|
CEM-SS
|
CC50 |
|
Cytotoxicity against human CEM-SS cells by MTT assay
Cytotoxicity against human CEM-SS cells by MTT assay
|
[PMID: 20112915]
|
CEM-SS
|
CC50 |
|
Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay
Cytotoxicity against human CEM-SS cells assessed as cell viability by XTT assay
|
[PMID: 21035347]
|
CEM-SS
|
CC50 |
|
Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
Cytotoxic concentration required to reduce the viability of mock infected CEM-SS cells by 50%.
|
[PMID: 9240351]
|
CEM-SS
|
CC50 |
|
Cytotoxicity against human CEM-SS cells by MTT assay
Cytotoxicity against human CEM-SS cells by MTT assay
|
[PMID: 19944610]
|
CEM-SS
|
CC50 |
|
Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
Antiviral activity in CEM-SS cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
|
[PMID: 7562927]
|
CEM-SS
|
CC50 |
|
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% in CEM-SS cells
|
[PMID: 12593658]
|
CEM-SS
|
CC50 |
> 100 μM
Compound: 1, AZT
|
Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
Cytotoxic conc. which reduces the cell viability of HIV-1 LAI infected T4 lymphoblastoid CEM-SS cells by 50%
|
[PMID: 10821705]
|
CEM-SS
|
CC50 |
|
Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human CEM-SS cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 33711763]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
CEM-SS
|
EC50 |
0.002 μM
Compound: AZT ; azidothymidine
|
Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay
Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay
|
[PMID: 27234889]
|
CEM-SS
|
IC50 |
|
Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay
Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as RT activity after 5 days by single passage assay
|
[PMID: 20112915]
|
CEM-SS
|
IC50 |
0.0026 μM
Compound: Zidovudine (AZT)
|
Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells
Compound was tested for activity against HIV-1 by syncytial plaque assay performed in duplicate using CEM-SS cells
|
[PMID: 9548815]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
EC50 |
|
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells
Effective concentration required to inhibit the replication of HIV-1 by 50% in CEM-SS cells
|
[PMID: 12593658]
|
CEM-SS
|
IC50 |
0.0031 μM
Compound: Zidovudine (AZT)
|
Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells
Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells
|
[PMID: 9548815]
|
CEM-SS
|
EC50 |
|
Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay
Effective concentration required for antiviral activity against HIV strain IIIB in CEM-SS cells by XTT assay
|
[PMID: 7932526]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B expressing nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
IC50 |
|
Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay
Antiviral activity against HIV1 LAI infected in human CEM-SS cells assessed as inhibition of viral replication by MTT assay
|
[PMID: 19944610]
|
CEM-SS
|
EC50 |
0.0053 μM
Compound: AZT, 3'-azidothymidine
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
|
[PMID: 24102161]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
CEM-SS
|
EC50 |
|
Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
Antiviral activity in CEM-SS cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
|
[PMID: 7562927]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
|
[PMID: 20086159]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM-SS cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 D1 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
EC50 |
|
Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells
Effective concentration required for 50% inhibition of viral replication by syncytium-forming assay carried out in CEM-SS cells
|
10.1016/0960-894X(95)00260-Z
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 A7 harboring Tyr127His mutation in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat
Antiviral activity against Human immunodeficiency virus 1 H10 harboring Tyr127His, Gly140Glu, Glu149Lys, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporat
|
[PMID: 20086149]
|
CEM-SS
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 A12 harboring Tyr127His, Asp174Asn and Arg178Lys mutations in nef protein infecting in CEM-SS cells assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
CEM-SS
|
EC50 |
|
Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay
Effective concentration required for antiviral activity against T cell line of CEM-SS cells of Human by XTT assay
|
[PMID: 7932526]
|
CEM-SS
|
EC50 |
|
Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells
Effective concentration required for 50% inhibition of viral replication by XTT cytoprotection assay carried out in CEM-SS cells
|
10.1016/0960-894X(95)00260-Z
|
CEM-SS
|
EC50 |
|
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
Antiviral activity against HIV-1 subtype 3B infected in CEM-SS cells assessed as inhibition of viral replication after 6 days by XTT assay
|
[PMID: 22858097]
|
CEM-SS
|
IC50 |
|
In vitro inhibition of CEM-SS cell growth by 50 %
In vitro inhibition of CEM-SS cell growth by 50 %
|
[PMID: 2016713]
|
CEM-TK(-)
|
EC50 |
|
Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%
Concentration required to protect CEM/TK cells against the cytopathicity of HIV-2 by 50%
|
[PMID: 11356105]
|
CEM-TK(-)
|
CC50 |
|
Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human CEM-TK(-) cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 33711763]
|
CEM-TK(-)
|
CC50 |
> 200 μg/mL
Compound: AZT
|
Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.
Cytotoxic concentration which is required to reduce CEM/TK- cell viability by 50%.
|
[PMID: 9046339]
|
CEM-TK(+)
|
EC50 |
|
Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
Antiviral activity in CEM/TK cell line infected with HIV-1 and Concentration required to inhibit the replication of HIV-1 by 50% was determined
|
[PMID: 7562927]
|
CEM-TK(+)
|
CC50 |
|
Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
Antiviral activity in CEM/TK cell line infected with HIV-1 and cytotoxic concentration required to reduce the viability of uninfected cells by 50%
|
[PMID: 7562927]
|
DU-145
|
IC50 |
34.45 μM
Compound: 13, AZT
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
Cytotoxicity against human DU145 cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
H9
|
IC50 |
< 0.0003 μM
Compound: AZT
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
H9
|
IC50 |
< 0.0003 μM
Compound: AZT
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
H9
|
IC50 |
< 0.0003 μM
Compound: AZT
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
H9
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
H9
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
H9
|
IC50 |
|
Cytotoxicity against human H9 cells by MTS assay
Cytotoxicity against human H9 cells by MTS assay
|
[PMID: 20086149]
|
H9
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA
|
[PMID: 20086149]
|
H9
|
EC50 |
|
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
|
[PMID: 11430019]
|
H9
|
EC50 |
|
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique
|
[PMID: 11430019]
|
H9
|
EC50 |
0.002 μg/mL
Compound: AZT
|
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
|
[PMID: 8946749]
|
H9
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
H9
|
EC50 |
0.00289 μg/mL
Compound: AZT
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral p24 antigen levels after 4 days by ELISA
|
[PMID: 11678650]
|
H9
|
EC50 |
|
Evaluation for anti-HIV activity using T cell line (H9).
Evaluation for anti-HIV activity using T cell line (H9).
|
10.1016/S0960-894X(97)10108-1
|
H9
|
EC50 |
|
Cytotoxicity against human H9 cells after 6 days by MTT assay
Cytotoxicity against human H9 cells after 6 days by MTT assay
|
[PMID: 20846868]
|
H9
|
EC50 |
0.012 μg/mL
Compound: AZT
|
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
|
[PMID: 9748372]
|
H9
|
EC50 |
0.012 μg/mL
Compound: AZT
|
Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%
Inhibitory concentration required to inhibit HIV replication in H9 lymphocytes growth by 50%
|
[PMID: 10021911]
|
H9
|
EC50 |
|
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
|
[PMID: 9804704]
|
H9
|
EC50 |
|
Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA
Antiviral activity against HIV1 3B in H9 cells after 4 days by p24-antigen ELISA
|
[PMID: 17190445]
|
H9
|
IC50 |
|
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 50 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay
|
[PMID: 20086149]
|
H9
|
IC50 |
|
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected H9 cells by 50 percent
|
[PMID: 1573638]
|
H9
|
EC50 |
|
Anti-HIV activity was measured in H9-cells by MAGI assay
Anti-HIV activity was measured in H9-cells by MAGI assay
|
[PMID: 9804704]
|
H9
|
ED50 |
|
Effective dose required to inhibit virus replication growth by 50%
Effective dose required to inhibit virus replication growth by 50%
|
[PMID: 8642556]
|
H9
|
EC50 |
|
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8176401]
|
H9
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8158164]
|
H9
|
EC50 |
|
Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined
Concentration of compound which inhibits virus replication of HIV by 50% (EC50 of 10 uM) in acutely infected H9 lymphocyte cells was determined
|
10.1016/S0960-894X(01)81071-4
|
H9
|
EC50 |
|
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
|
[PMID: 20187635]
|
H9
|
EC50 |
|
Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes
Concentration required to inhibit HIV-1 replication by 50% in acutely infected H9 lymphocytes
|
[PMID: 15149703]
|
H9
|
EC50 |
0.045 μg/mL
Compound: AZT
|
Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human H9 T cells after 4 days by ELISA
|
[PMID: 9917290]
|
H9
|
EC50 |
|
Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%
Anti-HIV activity was evaluated for the concentration that inhibits viral replication by 50%
|
10.1016/S0960-894X(97)10050-6
|
H9
|
EC50 |
|
Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%
Anti-HIV activity was evaluated as the concentration required to inhibit HIV-1 replication in H9 lymphocyte cells by 50%
|
[PMID: 9873374]
|
H9
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 days by p24 antigen based assay
|
[PMID: 20527972]
|
H9
|
IC50 |
|
Cytotoxicity against human H9 cells after 4 days
Cytotoxicity against human H9 cells after 4 days
|
[PMID: 17190445]
|
H9
|
IC50 |
|
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
|
[PMID: 11141100]
|
H9
|
IC50 |
|
Concentration required to inhibit uninfected H9 cell growth by 50%
Concentration required to inhibit uninfected H9 cell growth by 50%
|
[PMID: 14736256]
|
H9
|
CC50 |
|
Cytotoxicity against human H9 cells after 6 days by XTT assay
Cytotoxicity against human H9 cells after 6 days by XTT assay
|
[PMID: 20527972]
|
H9
|
IC50 |
|
Inhibitory activity against gorwth of uninfected H9 cell growth by 50%
Inhibitory activity against gorwth of uninfected H9 cell growth by 50%
|
10.1016/S0960-894X(97)10050-6
|
H9
|
IC50 |
|
Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%
Compound was evaluated for anti-HIV activity and the concentration that inhibits uninfected H9 cell growth by 50%
|
[PMID: 9873504]
|
H9
|
IC50 |
|
Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%
Anti-HIV activity was evaluated as the concentration required to inhibit the growth of uninfected H9 lymphocyte cells by 50%
|
[PMID: 9873374]
|
H9
|
IC50 |
|
Concentration required to inhibit uninfected H9 cell growth by 50%
Concentration required to inhibit uninfected H9 cell growth by 50%
|
[PMID: 15149703]
|
H9
|
IC50 |
|
Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%
Inhibitory concentration required to inhibit uninfected H9 cell growth by 50%
|
[PMID: 11527717]
|
H9
|
IC50 |
|
Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%
Inhibitory concentration required to inhibit uninfected growth of H9 lymphocytes by 50%
|
[PMID: 8642556]
|
H9
|
IC50 |
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8176401]
|
H9
|
IC50 |
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8158164]
|
H9
|
IC50 |
|
Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined
Concentration which inhibits uninfected cell growth of HIV by 50% (IC50>140 uM) in acutely infected H9 lymphocyte cells was determined
|
10.1016/S0960-894X(01)81071-4
|
H9
|
IC50 |
|
Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay
Tested for the inhibitory activity against HIV-1 in H-9 cell lines assessed by syncytium formation and reverse transcriptase assay
|
10.1016/0960-894X(95)00306-E
|
H9
|
IC50 |
|
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of p24 antigen production after 4 days by ELISA
|
[PMID: 8946749]
|
H9
|
IC50 |
|
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
|
[PMID: 9748372]
|
H9
|
IC50 |
|
Concentration that inhibits uninfected H9 cell growth by 50%.
Concentration that inhibits uninfected H9 cell growth by 50%.
|
[PMID: 12729671]
|
H9
|
IC50 |
|
Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%
Inhibitory concentration required to inhibit uninfected H9 lymphocytic cell growth by 50%
|
[PMID: 10021911]
|
H9
|
IC50 |
|
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay
Antiviral activity against HIV1 3B infected in human H9 cells assessed as inhibition of viral replication after 6 hrs by p24 antigen based assay
|
[PMID: 20846868]
|
HEK-293T
|
CC50 |
|
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method
|
[PMID: 17470654]
|
HEK-293T
|
EC50 |
|
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 695-RT infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
|
[PMID: 22148316]
|
HEK-293T
|
EC50 |
|
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
Antiviral activity against multidrug-resistant HIV1 106-PR infected in HEK293T cells assessed as inhibition of viral replication after 4 days by beta-galactosidase reporter gene assay
|
[PMID: 22148316]
|
HeLa
|
IC50 |
> 100 μM
Compound: AZT, Zidovudine
|
Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells at 125 uM after 48 hrs by MTT assay
|
[PMID: 17416522]
|
HeLa
|
IC50 |
> 100 μM
Compound: AZT, Zidovudine
|
Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells at 100 uM after 48 hrs by MTT assay
|
[PMID: 17416522]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
|
[PMID: 22858300]
|
HeLa
|
CC50 |
> 25 μM
Compound: Zidovudine
|
Cytotoxicity against mock-infected human HeLa cells by MTT assay
Cytotoxicity against mock-infected human HeLa cells by MTT assay
|
[PMID: 25682562]
|
HeLa
|
CC50 |
|
Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay
Cytotoxicity against human HeLa P4/R5 cells after 2 to 4 hrs by MTT assay
|
[PMID: 19596885]
|
HeLa
|
EC50 |
> 374 μM
Compound: 2, AZT, Zidovudine
|
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa P4/R5 cells after 48 hrs by MTT assay
|
[PMID: 22352809]
|
HeLa
|
EC50 |
|
Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay
Tested in vitro against HIV-1 104pre from HeLa-CD4-LT4-beta gal-cells using MAGI assay
|
[PMID: 11087576]
|
HeLa
|
EC50 |
|
Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes
Compound was tested for Anti-HIV activity by plaque reduction assay with E89K virus in HT4-6C human CD4+ lymphocytes
|
[PMID: 9258355]
|
HeLa
|
EC50 |
|
Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes
Compound was tested for Anti-HIV activity by plaque reduction assay with wild type HIV-1LAI virus in HT4-6C human CD4+ lymphocytes
|
[PMID: 9258355]
|
HeLa
|
IC50 |
|
Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry
Antiviral activity against VSV-G pseudotyped HIV1 lentiviral particles infected in human HeLa cells incubated for 48 hrs by spectrofluorometry
|
[PMID: 22858300]
|
HeLa
|
IC50 |
10.77 μM
Compound: 3; AZT
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
HeLa
|
EC50 |
10.8 μM
Compound: 2, AZT, Zidovudine
|
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 3B infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
|
[PMID: 22352809]
|
HeLa
|
EC50 |
14.2 μM
Compound: 2, AZT, Zidovudine
|
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
Antiviral activity against HIV1 BaL infected in HeLa P4/R5 cells assessed as reduction of viral infection incubated for 2 hrs followed by incubated in drug-free medium for 46 hrs by single round infection beta-galactosidase reporter gene assay
|
[PMID: 22352809]
|
HeLa
|
EC50 |
|
Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes
Compound was tested for Anti-HIV activity by plaque reduction assay with A018-post virus in HT4-6C human CD4+ lymphocytes
|
[PMID: 9258355]
|
HeLa
|
IC50 |
65.46 μM
Compound: 13, AZT
|
Cytotoxicity against human HeLa cells after 48 hrs by SRB method
Cytotoxicity against human HeLa cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
HepG2
|
IC50 |
> 400 μM
Compound: Azidothymidine
|
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
|
[PMID: 31546197]
|
HepG2
|
IC50 |
> 479 μM
Compound: AZT; Zidovudine
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition measured after 3 days by MTT assay
|
[PMID: 27342752]
|
HepG2
|
IC50 |
13.03 μM
Compound: 3; AZT
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
HL-60
|
IC50 |
|
Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
Cytotoxicity was tested in HL60 cells by the trypan blue exclusion assay.
|
[PMID: 1695683]
|
HOS
|
IC50 |
|
Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
|
[PMID: 19678643]
|
HOS
|
IC50 |
|
Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 reverse transcriptase M41L/D67N/K70R/T215Y/K219Q mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
|
[PMID: 19678643]
|
HOS
|
IC50 |
|
Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
|
[PMID: 19678643]
|
HOS
|
IC50 |
|
Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
Inhibition of HIV1 reverse transcriptase SSGR/T215Y mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay
|
[PMID: 19678643]
|
Huh-7
|
EC50 |
|
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as decrease in viral RNA level after 96 hrs by RT-PCR
|
[PMID: 22014549]
|
Huh-7
|
CC50 |
|
Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis
Cytotoxicity against human HuH7 cells assessed as reduction in rRNA levels at 120 hrs by RT-PCR analysis
|
[PMID: 23623492]
|
Huh-7
|
CC50 |
|
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
Cytotoxicity against human HuH7 cells assessed as reduction of 50% rRNA level after 96 hrs
|
[PMID: 22014549]
|
JM1
|
CC50 |
|
Concentration required to reduce cell viability of JM cells by 50%
Concentration required to reduce cell viability of JM cells by 50%
|
10.1016/0960-894X(96)00443-X
|
Jurkat
|
EC50 |
|
Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis
Antiviral activity against HIV1 pseudovirus infected in Jurkat cells coexpressing GFP assessed as viral growth inhibition incubated for 2 to 8 hrs prior to infection measured after 48 hrs by flow cytofluorimetric analysis
|
[PMID: 22954898]
|
Jurkat
|
IC50 |
|
Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay
Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay
|
[PMID: 21414776]
|
KB
|
IC50 |
> 400 μM
Compound: Azidothymidine
|
Antiproliferative activity against human KB cells by MTT assay
Antiproliferative activity against human KB cells by MTT assay
|
[PMID: 31546197]
|
KB
|
IC50 |
3.12 μg/mL
Compound: AZT, Zidovudine
|
Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
|
[PMID: 21945463]
|
KB
|
IC50 |
|
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940]
|
KB
|
IC50 |
|
Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
KB 3-1
|
IC50 |
9.17 μM
Compound: AZT, Zidovudine
|
Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay
|
[PMID: 25440502]
|
M
|
EC50 |
|
Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay
Effective concentration required for antiviral activity against M cell line of macrophage cells of Human by XTT assay
|
[PMID: 7932526]
|
MCF7
|
IC50 |
13.74 μM
Compound: AZT, Zidovudine
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 25440502]
|
MCF7
|
IC50 |
2.6 μg/mL
Compound: AZT, Zidovudine
|
Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay
|
[PMID: 21945463]
|
MCF7
|
IC50 |
34.97 μM
Compound: 13, AZT
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
Cytotoxicity against human MCF7 cells after 48 hrs by SRB method
|
[PMID: 25933593]
|
MCF7
|
IC50 |
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay
|
[PMID: 27501415]
|
MOLT-3
|
CC50 |
|
Cytotoxicity against human MOLT3 cells by MTS assay
Cytotoxicity against human MOLT3 cells by MTS assay
|
[PMID: 22549138]
|
MOLT-3
|
CC50 |
|
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay
|
[PMID: 21334901]
|
MOLT-4
|
EC50 |
|
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay
|
[PMID: 18316521]
|
MT2
|
CC50 |
|
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
|
[PMID: 20542430]
|
MT2
|
CC50 |
> 200 μM
Compound: AZT, zidovudine
|
Cytotoxicity against human MT2 cells after 5 days
Cytotoxicity against human MT2 cells after 5 days
|
[PMID: 19179082]
|
MT2
|
CC50 |
|
Cytotoxicity against human MT2 cells by MTT assay
Cytotoxicity against human MT2 cells by MTT assay
|
[PMID: 23570720]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay
Effective concentration required for antiviral activity against HIV strain IIIB in MT-2 cells by XTT assay
|
[PMID: 7932526]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay
Inhibition of HIV1 LAI replication in MT2 cells by cytopathic effect assay
|
[PMID: 17004726]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication treated 1 day after infection measured on after 4 days postinfection by p24 antigen ELISA
|
[PMID: 20329730]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production after 6 days by ELISA
|
[PMID: 20537902]
|
MT2
|
IC50 |
|
Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
Antiviral activity against HIV1 bearing VSV glycoprotein infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay
|
[PMID: 20542430]
|
MT2
|
IC50 |
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay
|
[PMID: 20728351]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
Antiviral activity against HIV1 3B infected in human MT2 cells assessed as p24 antigen level after 4 days by ELISA
|
[PMID: 19388685]
|
MT2
|
ED50 |
|
Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia
Effective antiviral dose required to block the spread of HIV-1 IIIb infection in MT-2 cells by monitoring the formation of syncytia
|
[PMID: 7512142]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
0.16 μM
Compound: AZT, zidovudine
|
Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay
Antiviral activity against HIV1 3a infected human MT2 cells assessed as inhibition of viral-induced cytopathic effect after 3 days by XTT assay
|
[PMID: 19179082]
|
MT2
|
EC50 |
|
Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days
Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days
|
[PMID: 17562366]
|
MT2
|
IC50 |
|
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced HIV-1 LAV infected MT-2 cells by 50 percent
|
[PMID: 1573638]
|
MT2
|
IC50 |
|
In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced H 112-2(pre-AZT) infected MT-2 cells by 50 percent
|
[PMID: 1573638]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
IC50 |
|
In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced G 762-3(pre-AZT) infected MT-2 cells by 50 percent
|
[PMID: 1573638]
|
MT2
|
EC50 |
|
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA
|
[PMID: 18316521]
|
MT2
|
EC50 |
|
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay
|
[PMID: 18316521]
|
MT2
|
IC50 |
|
In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced G 691-2(post-AZT) infected MT-2 cells by 50 percent
|
[PMID: 1573638]
|
MT2
|
CC50 |
|
Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay
Cytotoxicity against human MT2 cells after 2 to 4 days by MTT assay
|
[PMID: 19596885]
|
MT2
|
IC50 |
|
Cytotoxicity against human MT2 cells by XTT assay
Cytotoxicity against human MT2 cells by XTT assay
|
[PMID: 20329730]
|
MT2
|
CC50 |
|
Cytotoxicity against human MT2 cells by XTT assay
Cytotoxicity against human MT2 cells by XTT assay
|
[PMID: 19388685]
|
MT2
|
IC50 |
|
Cytotoxicity against MT2 cells by XTT assay
Cytotoxicity against MT2 cells by XTT assay
|
[PMID: 17935987]
|
MT2
|
IC50 |
|
Cytotoxicity against human MT2 cells after 6 days by XTT assay
Cytotoxicity against human MT2 cells after 6 days by XTT assay
|
[PMID: 20537902]
|
MT2
|
IC50 |
|
In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent
In vitro Cytotoxic concentration which reduced G 910-6p2 (post-AZT) infected MT-2 cells by 50 percent
|
[PMID: 1573638]
|
MT2
|
EC50 |
|
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
Antiviral activity against vesicular stomatitis virus G-pseudotyped Human immunodeficiency virus 1 NL4-3 infected in human MT2 cells assessed as inhibition of viral replication after 48 hrs by luciferase activity reporter gene assay
|
[PMID: 21745701]
|
MT4
|
CC50 |
> 0.00748 μM
Compound: AZT
|
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay
|
[PMID: 28481112]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay
|
[PMID: 26756779]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay
Cytotoxicity against human MT4 cells treated for 3 days measured by Celltiter-glo luminescent assay
|
[PMID: 33214842]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells measured after 3 days by CytoTox-Glo assay
|
[PMID: 31184480]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay
Cytotoxicity against human MT4 cells after 3 days by CytoTox-Glo assay
|
[PMID: 30031972]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay
|
[PMID: 28682067]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 22652226]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 20112915]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 4 days by MTT assay
Cytotoxicity against human MT4 cells after 4 days by MTT assay
|
[PMID: 23916148]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells after 5 days by MTT assay
Cytotoxicity against human MT4 cells after 5 days by MTT assay
|
[PMID: 22277590]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 26094944]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 19944610]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay
Cytotoxicity against human MT4 cells by MTT assay
|
[PMID: 17548498]
|
MT4
|
CC50 |
|
Tested in vitro against MT-4 cells using MTT assay
Tested in vitro against MT-4 cells using MTT assay
|
[PMID: 11087576]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine
|
[PMID: 26094944]
|
MT4
|
CC50 |
|
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells
Cytotoxic concentration required to reduce the viability of HIV-1 by 50% MT-4 cells
|
[PMID: 12593658]
|
MT4
|
CC50 |
> 100 μM
Compound: 1, AZT
|
Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
Cytotoxic conc. which reduces the cell viability of HIV-1 IIIB infected T4 lymphoblastoid MT-4 cells by 50%
|
[PMID: 10821705]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay
Cytotoxicity against human MT4 cells incubated for 3 days by CellTiter-Glo luminescent assay
|
[PMID: 31860304]
|
MT4
|
CC50 |
> 15 μM
Compound: Zidovudine
|
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay
|
[PMID: 31767136]
|
MT4
|
CC50 |
|
Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay
|
[PMID: 22712652]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 34583311]
|
MT4
|
CC50 |
> 2.5 μg/mL
Compound: Zidovudine
|
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
|
10.1007/s00044-011-9664-7
|
MT4
|
CC50 |
|
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
|
10.1016/S0960-894X(97)00340-5
|
MT4
|
CC50 |
|
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
Concentration required to reduce the viability of mock-infected MT-4 cells by 50%
|
[PMID: 8558522]
|
MT4
|
CC50 |
|
Compound dose required to reduce the viability of mock-infected cells by 50%
Compound dose required to reduce the viability of mock-infected cells by 50%
|
[PMID: 7650679]
|
MT4
|
CC50 |
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay
|
[PMID: 29353724]
|
MT4
|
CC50 |
> 25 μg/mL
Compound: Azidothymidine
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay
|
[PMID: 26707844]
|
MT4
|
CC50 |
> 25 μg/mL
Compound: Zidovudine
|
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay
|
10.1007/s00044-011-9776-0
|
MT4
|
CC50 |
> 25 μg/mL
Compound: Zidovudine
|
|